Sarepta Therapeutics, Inc. - Common Stock (SRPT)

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

NEW YORK CITY, NY / ACCESS Newswire / June 26, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for potential violations of the federal securities laws.

NEW YORK CITY, NY / ACCESS Newswire / June 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for potential violations of the federal securities laws.

NEW YORK CITY, NY / ACCESS Newswire / June 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK CITY, NY / ACCESS Newswire / June 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for potential violations of the federal securities laws.

NEW YORK CITY, NY / ACCESS Newswire / June 20, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for potential violations of the federal securities laws.

NEW YORK CITY, NY / ACCESS Newswire / June 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK CITY, NY / ACCESS Newswire / June 19, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for potential violations of the federal securities laws.

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

RADNOR, PA - June 17, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) (“Sarepta”).

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of the federal securities laws.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

RADNOR, PA - June 16, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) (“Sarepta”).

PHILADELPHIA, PA / ACCESS Newswire / June 16, 2025 / Kehoe Law Firm, P.C. is investigating potential violations of federal securities laws and claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ:SRPT).

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the Company is taking to strengthen the safety profile in non-ambulatory patients. These steps follow a second reported case of acute liver failure (ALF) resulting in death. The cases of ALF to date have both occurred in non-ambulatory individuals with Duchenne. Sarepta extends its deepest sympathies to the affected families and care teams.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the U.S. Food & Drug Administration.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

RADNOR, PA - May 29, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) (“Sarepta”).

RADNOR, PA - May 22, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) (“Sarepta”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.